Pioneer in biological accelerator mass spectrometry completes formation of founding scientific advisory board - team of scientific pioneers includes John Vogel and Bruce Hammock
Vitalea Science has completed formation of key members of its scientific advisory board.
The board consists of global thought leaders and pioneers in the field of drug discovery, nutrition, toxicology and accelerator mass spectrometry.
Each member of our founding scientific advisory board provides specific expertise and knowledge of a discipline that is critical to pushing biological innovation in the field of accelerator mass spectrometry and human microdosing.
To quote founding president, Stephen R Dueker: "The members of our board share our vision of ushering a new era of quantitative biology.
"Our core technology is the engine behind finding new ways to study drugs and other bioactive molecules such as phytonutrients in people as never before - we expect to replace inhumane and often useless animal testing with safe and accurate human trials for drug development, but this is really only the start.
"A new world of quantitative biology lies ahead, and with these key advisory members, Vitalea will be an innovative force in biomedical and drug research".
The board members are an elite makeup of technology founders, National Academy Science members, industry entrepreneurs and high-ranking academicians.
Members of the Vitalea scientific advisory board are:.
Chair, John Vogel, - senior scientist at the Center for Accelerator Mass Spectrometry (Cams), Lawrence Livermore National Laboratories (LLNL) and adjunct professor in the department of nutrition at the University of California , Davis.
Vogel, a world-renowned physicist, holds several key patents in AMS technology, including applications in biomedical research.
Bruce Hammock, distinguished professor of entomology and cancer research center and director of NIEHS-UCD Superfund basic research programme at University of California, Davis.
Hammock investigates new biological pest controls and analytical methods for detecting environmental contaminants.
Hammock's research efforts have had an exemplary impact on many different areas of biology, agriculture and medicine.
He has received numerous academic awards including the prestigious Alexander von Humboldt Award in 1995 for his research contributions to us agriculture and the burroughs wellcome Toxicology Scholar Award from the Society of Toxicology in 1987.
He was elected in 1999 to the National Academy of Sciences, one of the highest honours for scientists in the United States.
James Harris, co-founder and chief scientific officer of Bioavailability System (BAS) and the sole inventor of all BAS patents (except the synthetic chemistry series).
From 1991 to 1996, Harris worked for the FDA, Center for Drug Evaluation and Research, ultimately becoming a key member in clinical pharmacology research.
During that time he published papers on the elucidation of the metabolism of Taxol by CYP 3A and the isolation of the principal Taxol metabolite.
In 1996, Harris left the FDA in order to found Bioavailability Systems.
Carl Keen, professor and chairman of the department of nutrition at the University of California, Davis.
He is a pioneer in the study of the effect of diet on embryonic and fetal development and is a renowned authority in the health effects of phytonutrients.
A key emerging component of his programme is the application of AMS for answering important questions related to dietary flavonoid utilisation and metabolism.
Vitalea Science applies of accelerator technology, a powerful and new scientific approach for the discovery and testing of new drugs in humans.
Seasoned and successful entrepreneurs, as well as scientific pioneers, make up Vitalea's executive management team and scientific advisory board.
Accelerator technology is based on acclerator mass spectrometry (AMS), a tool developed in particle physics, that, in the last decade, has turned into a powerful platform for drug development.
A key application of accelerator technology is microdosing, where harmless small quantities of developmental drugs are evaluate in people without years of animal testing.
Vitalea's team of scientists is of a handful of global experts with detailed knowledge of conducting accelerator bases human studies.
